Ramatroban

Drug Profile

Ramatroban

Alternative Names: BAY-U-3405; Baynas

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer Yakuhin
  • Class Antiallergics; Carbazoles; Small molecules; Sulfonamides
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Allergic rhinitis
  • Discontinued Asthma; Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 10 Nov 2006 Discontinued - Phase-II for Allergic rhinitis in Spain (unspecified route)
  • 10 Nov 2006 Discontinued - Phase-II for Asthma in Spain (unspecified route)
  • 10 Nov 2006 Discontinued - Phase-III for Allergic rhinitis in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top